Ann: GE Healthcare to Distribute Osprey Medical Technology, page-243

GE sell a wide variety of contrast media (dye). The type of contrast used depends on the procedure and the scan method (MRI/CT/x-ray/ultrasound). The 3 patients every second refers to all forms of contrast across a wide range of procedures and scan methods. The contrast used in angiography procedures (for which Osprey's DyeVert is used to reduce the amount of contrast used) is iodine-based and this can be nephrotoxic (damaging to the kidneys) especially in patients who already have some sort of renal issues. The less contrast that is used in these cases, the better the patient outcome. DyeVert is used in cardiothoracic imaging procedures, however any procedure that uses contrast media, particularly iodine-based contrast media, sees that media excreted through the kidneys and therefore poses additional risk to at-risk patients. Theoretically, there is nothing stopping Osprey from broadening its contrast reduction technology to be used in other cardiovascular imaging procedures. You could also argue that reducing the amount of contrast used in all procedures (not just in at-risk patients) is desirable from a cost perspective across the worldwide hospital system. You could then argue that it would be prudent to treat every patient undergoing an imaging procedure with the DyeVert system as both a cost-saving measure and as a matter of medical prudence. Nephrotoxicity is a strange beast. If you have a lot of scans there might be cumulative and undetected damage over a period of time. Some people live with kidney disease for a long time before being diagnosed. In short, I see a bright future for Osprey's technology, current and future, in world's hospital systems.